Potassium chloride-SOLofarm Politvist concentrate 4% 10ml ampoules, 10pcs

Composition

of potassium chloride-40 mg

of dextrose (or glucose in terms of dry matter-334 mg

of hydrochloric acid solution 0.1 M-up to pH 3.0-4.0

water for injection-up to 1 ml

Pharmacological action

Pharmacotetapeutic group:

potassium preparation.

ATX code: A 121 BA 01

Pharmacological action:

The drug K+, restores the water-electrolyte balance. It has a negative chrono-and bathmotronic effect, in high doses – negative ino – and dromotropic, as well as moderate diuritic effect. In small doses, K+ dilates the coronary vessels, and in large doses, it narrows them. Participates in the process of conducting nerve impulses. When administered intravenously, it increases the release of epinephrine by the adrenal glands.

It activates many cytoplasmic enzymes, participates in the maintenance of intracellular osmotic pressure, protein-synthetic reactions, and amino acid transport. Improves skeletal muscle contraction in patients with muscular dystrophy, myasthenia gravis. Increasing the concentration of K+ reduces the risk of toxic effects of cardiac glycosides.

Indications

Hyperkalemia, complete atrioventricular block, adrenal insufficiency, chronic renal failure, concomitant therapy with potassium-sparing diuretics, metabolic disorders (acidosis, hypovolemia with hyponatremia), pregnancy, lactation, age up to 18 years (efficacy and safety have not been established).

Contraindications

-Hypersensitivity to the active ingredient and auxiliary components of the drug, to acetylsalicylic acid or other NSAIDs. – Complete or incomplete combination of bronchial asthma, recurrent nasal and paranasal sinus polyposis, angioedema or urticaria caused by intolerance to acetylsalicylic acid or other NSAIDs due to the existing probability of cross-sensitivity (including in the anamnesis). – Erosive and ulcerative lesions of the stomach and duodenum in the acute stage or recently transferred. – Inflammatory bowel diseases – Crohn’s disease or ulcerative colitis in the acute stage. – Severe liver and heart failure. – Severe renal insufficiency (if no hemodialysis is performed, creatinine clearance is less than 30 ml / min), progressive kidney diseases, including confirmed hyperkalemia. – Active liver disease. – Active gastrointestinal bleeding, recent cerebrovascular bleeding, or an established diagnosis of diseases of the blood coagulation system. – Under 18 years of age. – Therapy of perioperative pain during coronary artery bypass grafting. – Concomitant therapy with anticoagulants, as there is a risk of formation of intramuscular hematomas. – Pregnancy. – The period of breastfeeding. With caution: – A history of diseases of the gastrointestinal tract (GIT) (presence of Helicobacter pylori infection). – Congestive heart failure. – Renal insufficiency (creatinine clearance 30-60 ml / min). – Coronary heart disease. – Cerebrovascular diseases. – Dyslipidemia/hyperlipidemia. – Diabetes mellitus. – Concomitant therapy with the following drugs: anticoagulants, oral glucocorticosteroids, antiplatelet agents, selective serotonin reuptake inhibitors. – Diseases of the peripheral arteries. – Advanced age. – Long-term use of NSAIDs. – Smoking. – Frequent use of alcohol.

Side effects

Nervous system disorders, paresthesia, muscle weakness, confusion. From the cardiovascular system: low blood pressure, arrhythmias, heart block, cardiac arrest. Other: hyperkalemia, allergic reactions.

Interaction

Pharmacologically compatible with cardiac glycoside solutions (improves their tolerability). Increases the negative dromo – and bathotropic effect of antiarrhythmic drugs. As part of a polarizing mixture (in combination with dextrose and insulin), it helps to normalize the heart rate in cases of myocardial infarction, ectopic arrhythmias and overdose with cardiac glycosides. Eliminates gynokalemia caused by glucocorticosteroids, mineralocorticosteroids and diuretics. Beta-blockers, cyclosporine, potassium-sparing diuretics, heparin, angiotensin converting enzyme inhibitors, and nonsteroidal anti-inflammatory drugs may increase the risk of hyperkalemia.

How to take, course of use and dosage

Intravenously. In case of hypokalemia with cardiac arrhythmia-1-1.5 g 4-5 times a day; after restoring the heart rate, the dose is reduced. With digitalis intoxication-2-3 g/day, in severe cases-up to 5 g. To stop paroxysmal tachycardia attacks on the first day-8-12 g, followed by a decrease to 3-6 g. Intravenously jet, if necessary intravenously drip (slowly, for 1 hour) – 2-2.5 g in 500 ml of 5% dextrose solution. For the prevention and treatment of ectopic arrhythmias in myocardial infarction-a polarizing mixture: a solution of potassium chloride in 5% – 10% dextrose solution (add insulin at the rate of 1 UNIT per 3-4 g of dry dextrose).

Overdose

Symptoms: hyperkalemia (muscle hypotension, paresthesia of the extremities, slowing of atrioventricular conduction, arrhythmias, cardiac arrest). Early clinical signs of hyperkalemia usually appear when serum K+ concentrations exceed 6 mEq / L; T wave sharpness, U wave disappearance, ST segment reduction, QT interval prolongation, QRS complex expansion. More severe symptoms of hyperkalemia – muscle paralysis and cardiac arrest-develop at a concentration of K+ 9-10 meq/l. Treatment: oral or intravenous – NaCl solution; intravenous-300-500 ml of 5% dextrose solution (with 10-20 units of insulin in 1 liter); if necessary – hemodialysis and peritoneal dialysis.

Special instructions

During treatment, it is necessary to monitor the content of K+ in the blood serum, ECG, in the treatment of hypokalemia – control of the acid-base state. The safety and efficacy of potassium chloride in children have not been established. If necessary, use during pregnancy should compare the expected benefit to the mother and the potential risk to the fetus. During lactation, you should decide whether to stop breastfeeding. A diet high in sodium chloride increases the elimination of K+ from the body. It should be borne in mind that hyperkalemia, which leads to a fatal outcome, can develop quickly and be asymptomatic.

Form of production

Solution for intramuscular use of 40 mg / ml.

Storage conditions

Store in a dry place protected from light at a temperature of 0 to +30 °C. Keep out of reach of children.

Shelf

life is 3 years. Do not use after the expiration date.

Active ingredient

Potassium Chloride

Conditions of release from pharmacies

By prescription

Dosage form

infusion solution